Christopher Kiritsy
Director/Board Member at PIERIS PHARMACEUTICALS, INC.
Net worth: 2 900 $ as of 2024-04-29
Network origin in Christopher Kiritsy first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 28 | |
| Public Company | Miscellaneous Commercial Services | 11 | |
Arisaph Pharmaceuticals, Inc.
 Arisaph Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arisaph Pharmaceuticals, Inc. provides drug discovery services. It has various drug discovery programs to develop therapies for diabetes, cancer, and cardiovascular disease. The company was founded by Michael Jaharis, Christopher P. Kiritsy, and William Bachovchin in 1999 and is headquartered in Boston, MA
8
| Private Company | Pharmaceuticals: Major | 8 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Christopher Kiritsy via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
KOS Pharmaceuticals, Inc.
 KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member Director/Board Member | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| MORPHOSYS AG | Biotechnology | General Counsel Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| SANOFI | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Operating Officer | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| University of Massachusetts | College/University | Undergraduate Degree Corporate Officer/Principal | |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of Toronto | College/University | Undergraduate Degree Doctorate Degree | |
| JUNIPER PHARMACEUTICALS INC | Pharmaceuticals: Major | Chairman Comptroller/Controller/Auditor | |
Pearl Therapeutics, Inc.
 Pearl Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| NEXTCURE, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
Pieris Pharmaceuticals GmbH
 Pieris Pharmaceuticals GmbH BiotechnologyHealth Technology Part of Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH operates as a German biotechnology company. The private company is based in Hallbergmoos, Germany. The CEOs of the company are Hitto Kaufmann, Stephen S. Yoder. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
| George Mason University | College/University | Undergraduate Degree Undergraduate Degree | |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Key Pharmaceuticals, Inc.
 Key Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Key Pharmaceuticals, Inc. operates as a subsidiary of Schering-Plough which is engaged in manufacturing, fabricating or processing drugs in pharmaceutical preparations. The company is located in Newark, NJ | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Administrative Officer Chief Tech/Sci/R&D Officer | |
| TRANSGENE | Biotechnology | Director/Board Member Director/Board Member | |
Ventana Medical Systems, Inc.
 Ventana Medical Systems, Inc. Electronic Equipment/InstrumentsElectronic Technology Ventana Medical Systems, Inc. develops tissue-based diagnostic solutions. It designs and delivers medical diagnostic systems and slide-based cancer tests. Its products include absolute Eosinophil count (AEC) detection kit intended for laboratory use to identify targets by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded tissue or frozen tissue on a BenchMark and BenchMark XT instrument and DISCOVERY XT research instrument that brings automation, reproducibility, and productivity to IHC and in situ hybridization (ISH) slide preparation and processing. The company was founded by Thomas M. Grogan in 1985 and is headquartered in Phoenix, AZ. | Electronic Equipment/Instruments | Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
AbCellera Boston, Inc.
 AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Biotechnology | Director/Board Member | |
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Biotechnology | Director/Board Member | |
| CUE BIOPHARMA, INC. | Biotechnology | Director/Board Member | |
| SUCAMPO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| AMBRX INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Zyngenia, Inc.
 Zyngenia, Inc. Drugstore ChainsRetail Trade Zyngenia, Inc. developed new class of bio-therapeutics. The company was founded by Joseph L. Amprey III, Carlos F. Barbas III and Peter Alec Kiener in 2008 and headquartered in Gaithersburg, MD. | Drugstore Chains | Founder | |
| GT BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Investment Managers | Private Equity Investor | |
| University of Oxford | College/University | Corporate Officer/Principal | |
Itolerance, Inc.
 Itolerance, Inc. BiotechnologyHealth Technology Itolerance, Inc. is an American biotechnology company that specializes in developing regenerative medicines. The private company was founded by Cameron Gray and is currently led by CEO Anthony J. Japour. | Biotechnology | Director/Board Member | |
Resolve Therapeutics LLC
 Resolve Therapeutics LLC BiotechnologyHealth Technology Resolve Therapeutics LLC operates as a biotechnology company. It engages in the development of biotechnology drugs. The firm specializes in treatment of debilitating autoimmune diseases such as Systemic Lupus Erythematous and Sjogren’s syndrome. The company was founded by James Posada in 2010 and is headquartered in Seattle, WA. | Biotechnology | Chairman | |
Cereius, Inc.
 Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Biotechnology | Chief Executive Officer | |
ONK Therapeutics Ltd.
 ONK Therapeutics Ltd. BiotechnologyHealth Technology ONK Therapeutics Ltd. develops bio cells for anti cancer therapies. The company was founded by Michael O'Dwyer and Anthony Killarney in 2015 and is headquartered in Galway, Ireland. | Biotechnology | Director/Board Member | |
| TEMPEST THERAPEUTICS, INC. | Pharmaceuticals: Major | President | |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Biotechnology | Chief Executive Officer | |
| University of Colorado Health Sciences Center | College/University | Doctorate Degree | |
Chiron Viagene, Inc.
 Chiron Viagene, Inc. Miscellaneous Commercial ServicesCommercial Services Chiron Viagene, Inc. provides technical services and life science research. The company is based in San Diego, CA. The company specializes in EMSA reagents and services, as well as producing innovative technology. The company was founded by Paul K. Laikind, David F. Hale, Jack W. Reich, Harry E. Gruber. Chiron Viagene was acquired by Chiron Corp. on October 03, 1995 for $135 million. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| University of California, Berkeley | College/University | Undergraduate Degree | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| IMMUNE DESIGN CORP | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer |
Statistics
International
| United States | 40 |
| Germany | 4 |
| United Kingdom | 4 |
| France | 3 |
| Sweden | 2 |
Sectoral
| Health Technology | 35 |
| Consumer Services | 7 |
| Finance | 4 |
| Commercial Services | 4 |
| Technology Services | 2 |
Operational
| Director/Board Member | 222 |
| Corporate Officer/Principal | 89 |
| Independent Dir/Board Member | 63 |
| Director of Finance/CFO | 43 |
| Undergraduate Degree | 37 |
Most connected contacts
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Harry Allan George | 27 |
| Donnie Hardison | 27 |
| Ann Hanham | 26 |
| Peter Kiener | 25 |
| James Geraghty | 25 |
| Darlene Deptula-Hicks | 24 |
| Jean Bizzari | 24 |
| Julian Adams | 22 |
| Michelle Griffin | 18 |
| Lee Roy McCracken | 17 |
| Michael Richman | 16 |
| Matthew Sherman | 16 |
| Steven Prelack | 15 |
| Kevin Thomas Ferro | 15 |
- Stock Market
- Insiders
- Christopher Kiritsy
- Company connections